Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kurata, T.
Right arrow Articles by Fukuoka, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurata, T.
Right arrow Articles by Fukuoka, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:173-174, 2004
© 2004 European Society for Medical Oncology

Effect of re-treatment with gefitinib (‘Iressa’, ZD1839) after acquisition of resistance

T. Kurata, K. Tamura, H. Kaneda, T. Nogami, H. Uejima, G. Asai, K. Nakagawa and M. Fukuoka*

Department of Medical Oncology, Kinki University School of Medicine, 377-2 Ohno-Higashi Osaka-Sayama, Osaka 589-8511, Japan

*E-mail: mfukuoka@med.kindai.ac.jp

The first 10% of the full text of this article appears below.

A 70-year-old man with adenocarcinoma of the lung developed pulmonary metastases 7 months after middle and lower lobectomy of the right lung in October 1998. He received four courses of first-line chemotherapy with docetaxel/irinotecan from June to September 1999. The best response was stable disease and, after 6 months of treatment, there was evidence of progressive disease with . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NEJMHome page
L. V. Sequist, J. E. Settleman, J. B. Ackman, and A. J. Iafrate
Case 23-2008 -- A 26-Year-Old Man with Back Pain and a Mass in the Lung
N. Engl. J. Med., July 24, 2008; 359(4): 405 - 414.
[Full Text] [PDF]

Home page
 Genes Dev.Home page
S. V. Sharma and J. Settleman
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Genes & Dev., December 15, 2007; 21(24): 3214 - 3231.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Guo, J. Lu, A. Subramanian, and G. E. Sonenshein
Microarray-Assisted Pathway Analysis Identifies Mitogen-Activated Protein Kinase Signaling as a Mediator of Resistance to the Green Tea Polyphenol Epigallocatechin 3-Gallate in Her-2/neu-Overexpressing Breast Cancer Cells.
Cancer Res., May 15, 2006; 66(10): 5322 - 5329.
[Abstract] [Full Text] [PDF]